- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (clinicaltrials.gov) - Mar 21, 2023 P1/2, N=123, Recruiting, Trial completion date: Sep 2025 --> Jul 2023 | Trial primary completion date: Sep 2025 --> Jul 2023 N=72 --> 123 | Trial completion date: Jun 2028 --> Feb 2026 | Trial primary completion date: Jun 2028 --> Feb 2026
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Enrollment change, Trial termination: Steroid Use in Non-RSV Bronchiolitis (clinicaltrials.gov) - Mar 21, 2023 P4, N=3, Terminated, N=72 --> 123 | Trial completion date: Jun 2028 --> Feb 2026 | Trial primary completion date: Jun 2028 --> Feb 2026 N=50 --> 3 | Active, not recruiting --> Terminated; COVID19-pandemic, RSV surge
- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Enrollment open, Trial completion date, Trial primary completion date: TORES: Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice (clinicaltrials.gov) - Mar 21, 2023 P=N/A, N=3050, Recruiting, N=50 --> 3 | Active, not recruiting --> Terminated; COVID19-pandemic, RSV surge Active, not recruiting --> Recruiting | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Oct 2023
- |||||||||| dexamethasone / Generic mfg.
Journal: Cationic lipid-conjugated bis-arylidene oxindole derivatives as broad-spectrum breast cancer-selective therapeutics. (Pubmed Central) - Mar 20, 2023 Hence, we have shown successful incorporation of dexamethasone to the self-assemblies, and its enhanced cytotoxicity even in ER-negative breast cancer cells. All these results indicate that PGC8, S2C8 and S3C8 molecules, albeit their potent and selective ER-positive anti-breast cancer activity, can be repurposed as targeted delivery systems and hold promise as unique, broader spectrum breast cancer cell-selective therapeutic payloads.
- |||||||||| dexamethasone / Generic mfg.
Journal: Design, Optimization and Evaluation of Dexamethasone-Loaded Microneedles for Inflammatory Disorders. (Pubmed Central) - Mar 20, 2023 Cytokine analysis also revealed that application of MN arrays downregulated the expressions of pro-inflammatory cytokines and upregulated the expressions of anti-inflammatory cytokines. Overall, the findings suggest that MN array could be a safe, easy, effective and minimally invasive alternative to the existing means of Dex delivery and could potentially be used for the treatment of inflammatory disorders.
- |||||||||| dexamethasone / Generic mfg., doxycycline / Generic mfg.
Preclinical, Journal: Doxycycline-doped collagen membranes accelerate in vitro osteoblast proliferation and differentiation. (Pubmed Central) - Mar 20, 2023 Reduced intolerability and substantial cost savings can be achieved by implementing a structured acute pediatric wheeze algorithm and modifying the OCS to single-dose dexamethasone (300?mcg/kg). The functionalization of collagen membranes with Dox promoted an increase in the proliferation and differentiation of osteoblasts.
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Ozurdex (dexamethasone intravitreal implant) / AbbVie, Exparel (bupivacaine liposome injectable suspension) / Pacira
Trial primary completion date: Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty (clinicaltrials.gov) - Mar 20, 2023 P4, N=60, Recruiting, Trial primary completion date: May 2025 --> Feb 2025 Trial primary completion date: Oct 2022 --> Apr 2023
- |||||||||| miricorilant (CORT118335) / Corcept Therap
Trial completion date, Trial initiation date, Trial primary completion date: Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant (clinicaltrials.gov) - Mar 20, 2023 P1, N=36, Recruiting, Trial primary completion date: Dec 2023 --> Sep 2022 Trial completion date: Jan 2023 --> Mar 2024 | Initiation date: Oct 2022 --> Mar 2022 | Trial primary completion date: Jan 2023 --> Mar 2024
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Trial completion date, Trial primary completion date: Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome (clinicaltrials.gov) - Mar 20, 2023 P=N/A, N=60, Recruiting, Trial completion date: Jan 2023 --> Mar 2024 | Initiation date: Oct 2022 --> Mar 2022 | Trial primary completion date: Jan 2023 --> Mar 2024 Trial completion date: Jul 2022 --> Jul 2025 | Trial primary completion date: Dec 2021 --> Dec 2024
- |||||||||| Decadron (dexamethasone) / Merck (MSD)
Trial completion date, Trial primary completion date: Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma (clinicaltrials.gov) - Mar 20, 2023 P2, N=40, Recruiting, Trial completion date: Jul 2022 --> Jul 2025 | Trial primary completion date: Dec 2021 --> Dec 2024 Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., cytarabine / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 20, 2023 P2, N=19, Completed, Active, not recruiting --> Recruiting Recruiting --> Completed | N=32 --> 19 | Trial completion date: Jun 2025 --> Dec 2022
- |||||||||| dexamethasone / Generic mfg.
Lactate and Amino Acids Support Increased Hepatic Glucose Production During Growth Restriction in Fetal Sheep. (Great Hall 3&4, Foyer Level) - Mar 20, 2023 - Abstract #SRI2023SRI_781; Additionally, intrinsic effects in IUGR hepatocytes maintain the increased capacity for HGP. These results are important because the early activation of HGP in the IUGR fetus may represent an adaptive response to ensure survival during placental insufficiency, however, intrinsic programming may underly uncontrolled HGP and T2D risk in IUGR offspring into adulthood.
- |||||||||| hydrocortisone / Generic mfg.
Glucocorticoid Receptor Isoform GR?-D1 Modulates a Pro-Inflammatory Environment in Placental Trophoblasts. (Great Hall 3&4, Foyer Level) - Mar 20, 2023 - Abstract #SRI2023SRI_610; BeWo human trophoblast cells were cultured and treated with lipopolysaccharide (LPS; 1 ?g/mL) with/without hydrocortisone (HC; 1 ?M) for measurement of GR isoform expression and downstream inflammatory mediators... GR?-D1 appears to play a key role in the interaction between stress and inflammation in the placenta potentially driving adverse fetal outcomes that could include preterm delivery, growth restriction and stillbirth.
- |||||||||| dexamethasone / Generic mfg.
Reduced Expression of Alcohol Dehydrogenase 1B in Uterine Leiomyoma. (Great Hall 3&4, Foyer Level) - Mar 20, 2023 - Abstract #SRI2023SRI_514; These results indicated that increased FKBP51 in uterine LM may dysregulate the RA pathway by reducing ADH1B levels to promote cell differentiation toward a secretory smooth muscle cell type, leading to increase in ECM deposition. Silencing FKBP51 levels increases ADH1B expression, suggesting a novel therapy for uterine fibroid targeting cellular differentiation.
- |||||||||| trimethoprim/sulfamethoxazole / Generic mfg.
Conventional-dose versus half-dose of sulfamethoxazole (Poster Tour Auditorium 11) - Mar 18, 2023 - Abstract #EULAR2023EULAR_1385; This dual-targeting scaffold effectively attenuated synovitis, decreased cartilage degeneration, and achieved complete relief of joint pain in two distinct rodent models of OA. Inclusion criteria were follows: aged over 20 years; admission to our hospitals for diagnosis and/or treatment of new-onset or relapsed systemic rheumatic diseases from April 1, 2018, to March 31, 2021; current treatment with at least 0.6 mg/kg/day of oral prednisolone or equivalent doses of corticosteroids with or without any immunosuppressant; no prior treatment with SMX/TMP, pentamidine isethionate, dapsone, or atovaquone; Serum creatinine levels within the institution
- |||||||||| Elrexfio (elranatamab-bcmm) / Pfizer, maplirpacept (TTI-622) / Pfizer
Trial completion date, Combination therapy: MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 17, 2023 P1b, N=14, Recruiting, Inclusion criteria were follows: aged over 20 years; admission to our hospitals for diagnosis and/or treatment of new-onset or relapsed systemic rheumatic diseases from April 1, 2018, to March 31, 2021; current treatment with at least 0.6 mg/kg/day of oral prednisolone or equivalent doses of corticosteroids with or without any immunosuppressant; no prior treatment with SMX/TMP, pentamidine isethionate, dapsone, or atovaquone; Serum creatinine levels within the institution Trial completion date: Nov 2026 --> Aug 2026
- |||||||||| Monjuvi (tafasitamab-cxix) / MorphoSys, Xencor, Incyte, Specialised Therap, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open: Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 17, 2023 P2, N=30, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
|